Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies

Background: Signet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease. Methods: Using test ( n =26) and validation ( n =18) cohorts, analysis of mutations, DNA methylation and transcr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer Jg. 117; H. 2; S. 203 - 209
Hauptverfasser:	Alvi, Muhammad A, Loughrey, Maurice B, Dunne, Philip, McQuaid, Stephen, Turkington, Richard, Fuchs, Marc-Aurel, McGready, Claire, Bingham, Victoria, Pang, Brendan, Moore, Wendy, Maxwell, Perry, Lawler, Mark, James, Jacqueline A, Murray, Graeme I, Wilson, Richard H, Salto-Tellez, Manuel
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 11.07.2017 Nature Publishing Group
Schlagworte:	631/208/727 692/4028/67/1059/2325 692/4028/67/1059/602 692/4028/67/1504/1885 Adaptive immunity Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Signet Ring Cell - genetics Carcinoma, Signet Ring Cell - pathology CD3 antigen Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology CpG islands CpG Islands - genetics DNA methylation DNA Methylation - genetics Drug Resistance Epidemiology Female Gene expression Gene Expression Regulation, Neoplastic Genomics Genotype Genotypes Humans Immune checkpoint inhibitors Immunohistochemistry Lymphoid cells Male Microsatellite Instability Molecular Medicine Mutation Neoplasm Proteins - biosynthesis Oncology Precision medicine Proto-Oncogene Proteins B-raf - genetics Statistical analysis Transcriptome - genetics Translational Therapeutics PDL1 KIT genotype
ISSN:	0007-0920, 1532-1827, 1532-1827
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!